Latest Coagulation system Stories
DALLAS, November 20, 2012 /PRNewswire/ -- - RnRMarketResearch.com adds new market research reports "Antithrombotic / Anticoagulant Drugs: Technologies and Global Markets" to its store. This report provides an overview of the global market for antithrombotic/anticoagulant drugs, which is changing due to factors such as an aging population, an increase in thrombotic events, and recent advances in pharmaceuticals. Analyses of global market trends, with data from 2011,...
ORLANDO, Fla., Nov. 8, 2012 /PRNewswire/ -- A coalition of leaders in hemophilia advocacy and treatment today announced a nationwide program that will offer free genetic testing to people with hemophilia and their families. The partnership will be officially unveiled this evening at the 64(th) National Hemophilia Foundation (NHF) Annual Meeting in Orlando, Florida. To view the multimedia assets associated with this release, please click:...
The cause of heart attacks or strokes among some patients treated with anti-platelet drugs may be different than for patients who have undergone surgical procedures to restore blood flow, according to researchers at Duke Medicine. The finding -- reported Nov. 4, 2012, at the American Heart Association's Scientific Sessions annual meeting and published in the Journal of the American Medical Association – provides new insights into a subset of heart patients with acute coronary syndromes...
CARLSBAD, Calif., Oct. 29, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 comparator-controlled study evaluating ISIS-FXI(Rx) in patients undergoing knee replacement surgery, also referred to as total knee arthroplasty (TKA). ISIS-FXI(Rx) inhibits the production of Factor XI, a coagulation factor produced in the liver that is involved in the formation of clots. In this study, Isis will evaluate the effectiveness of ISIS-FXI(Rx)...
BEIJING, Oct. 24, 2012 /PRNewswire-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. ("Taibang") has received good manufacturing practice ("GMP") certification from the China State Food and Drug Administration ("SFDA") for Human Coagulation Factor VIII ("FVIII")....
MONTREAL, Oct. 24, 2012 /PRNewswire/ - Pfizer Hemophilia is donating more than 35 million IUs of its recombinant factor IX therapy to the World Federation of Hemophilia (WFH) to help hemophilia B patients in underserved regions of the world. "This donation has the potential to impact people living with hemophilia B in more than 40 countries worldwide," said Alain Weill, WFH president. "The WFH relies on these donations to advance our goal of improving and introducing treatment...
CAMBRIDGE, Mass., Sept. 13, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc., an emerging biopharmaceutical company developing new treatment options for people with hemophilia, today announced that John P. Butler, Chief Executive Officer, will present at the UBS Global Life Sciences Conference on Thursday, September 20, 2012. The presentation will take place at 4:00 p.m. ET at the Grand Hyatt Hotel in New York. About Inspiration BiopharmaceuticalsAs the only...
LONDON and MOSCOW, September 11, 2012 /PRNewswire/ -- Subcutaneous blood factors expected to revolutionise the treatment paradigm of haemophiliac patients worldwide Pro Bono Bio Group plc ("PBB"), the international healthcare group, announces the successful conclusion of a series of pre-clinical trials in haemophiliac subjects conducted with the world's first long acting blood Factors VIIa, VIII and IX capable of subcutaneous...
Progress toward a new emergency treatment for internal bleeding ― counterpart to the tourniquets, pressure bandages and Quick Clot products that keep people from bleeding to death from external wounds ― was reported here today at the 244th National Meeting & Exposition of the American Chemical Society, the world's largest scientific society. Erin Lavik, Sc.D., who described the advance toward developing synthetic platelets, said it is among the efforts underway world-wide to treat...
CAMBRIDGE, Mass., Aug. 21, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals Inc. (Inspiration) today announced new license, development and commercialization agreements with its strategic partner, Ipsen (Euronext: IPN, ADR: IPSEY). The agreements restructure the existing partnership with Ipsen and provide Inspiration with additional funding to support development of its two investigational drugs in late-stage development for hemophilia, IB1001 and OBI-1. Under the terms of...
